TargetBeta
TNKS
tankyrase · also TIN1, TINF1, TNKS1, PARP-5a · Ankyrin repeat domain containing
1 program in company-led studies act on TNKS, from 1 company: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| nesuparibrule | Jeil Pharmaceutical | inhibitor | phase 2 | 43 running | PARP1, PARP2, TANK | NCIt |
Conditions their studies are in
- Ovarian Neoplasms, 1 program
- Stomach Neoplasms, 1 program
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.